Vasculitis News and Research

Latest Vasculitis News and Research

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced that several new data analyses from Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be presented at The International Liver CongressTM / 46th European Association for the Study of the Liver annual meeting.

9 Mar 2011

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the first quarter ended December 31, 2010.

28 Feb 2011

SQI fourth quarter net loss increases to $2,621,000

21 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

A new study shows that vitamin D deficiency could be linked to the development and severity of certain autoimmune lung diseases.

4 Jan 2011

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced additional positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

10 Nov 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Health Canada issues license for IgX PLEX Celiac test kit

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, announced today that Health Canada has issued a medical device license for its automated IgX PLEX Celiac(TM) microarray test kit that runs on the Company's automated SQiDworks(TM) platform. The license allows the Company to market and sell the IgX PLEX Celiac product in Canada.

21 Sep 2010

SQI Diagnostics 2010 third quarter net loss increases to $1,613K

SQI Diagnostics Inc.,a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced its financial and operational results for the third quarter ended June 30, 2010.

30 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

FDA designates XOMA 052 orphan drug for Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.

5 Aug 2010

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt.

29 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Scientists comment on two clinical trials that use Rituximab to treat small-vessel vasculitis

Two UNC School of Medicine faculty authored an editorial in the July 15, 2010 New England Journal of Medicine commenting on results from two clinical trials using the drug Rituximab to treat small-vessel vasculitis, a rare autoimmune disease.

15 Jul 2010

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET (sitagliptin/metformin) to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.

28 Jun 2010

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

Gamma-Dynacare to implement SQI's SQiDworks diagnostics platform

SQI Diagnostics Inc., a medical systems company focused on evolving laboratory-based biomarker testing, today announced that Gamma-Dynacare Medical Laboratories, one of Canada's largest providers of laboratory services, has agreed to put into operation SQI's SQiDworks(TM) platform, and to purchase SQI's multiplexed IgXplex(TM) Rheumatoid Arthritis consumables to meet its commercial needs.

17 Jun 2010

SQI Diagnostics second-quarter net loss increases to $2,021,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced its financial and operational results for the second quarter ended March 31, 2010.

1 Jun 2010

Vasculitis News and Research

Latest Vasculitis News and Research

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

SQI Diagnostics first quarter net loss increases to $2,255,000

SQI fourth quarter net loss increases to $2,621,000

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

VYTORIN reduces major vascular events in patients with chronic kidney disease

Positive results from XOMA 052 study in patients with uveitis of Behcet's disease

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Health Canada issues license for IgX PLEX Celiac test kit

SQI Diagnostics 2010 third quarter net loss increases to $1,613K

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

FDA designates XOMA 052 orphan drug for Behcet's disease

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Scientists comment on two clinical trials that use Rituximab to treat small-vessel vasculitis

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

Gamma-Dynacare to implement SQI's SQiDworks diagnostics platform

SQI Diagnostics second-quarter net loss increases to $2,021,000

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Vasculitis News and Research

Latest Vasculitis News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in